Drug resistance continues to limit the long-term benefit of many targeted therapies and chemotherapies against cancer. While “classical” small-molecule ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

In this Teach Me in 10, Dr. Sam Jensen provides a comprehensive overview of the tools, assays and strategies needed at each ...

A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...

Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies. This story was originally published on BioPharma Dive. To receive ...

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies The latest data presented for the three lead CELMoD agents and BCL6 LDD ...

Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated ...

Targeted protein degradation is a therapeutic strategy that utilizes the cell’s natural machinery to eliminate disease-causing proteins. The field traces its origins to the development of thalidomide ...